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Abstract
Background: Head and neck cancer (HNC) incidence, mortality and survival rates vary by sex and race, with men and African
Americans disproportionately affected. Risk factors for HNC include tobacco and alcohol exposure, with a recent implication
of human papillomavirus (HPV) in the pathogenesis of HNC. This study describes the epidemiology of HNC in the United
States, examining variation of rates by age, sex, race/ethnicity and potential HPV-association.
Methods: We used the North American Association of Central Cancer Registries (NAACCR) Cancer in North America (CINA)
Deluxe Analytic Data to analyze HNC incidence for 1995–2005 from forty population-based cancer registries. We calculated
age-adjusted incidence rates and incidence trends using annual percent change by age, sex, race/ethnicity and HPV-
association.
Results: Males and Non-Hispanic Blacks experienced greater HNC incidence compared to women and other race/ethnicity
groupings. A significant overall increase in HNC incidence was observed among HPV-associated sites during 1995–2005,
while non HPV-associated sites experienced a significant decline in HNC incidence. Overall, younger age groups, Non-
Hispanic Whites and Hispanics experienced greater increases in incidence for HPV-associated sites, while HNC incidence
declined for Non-Hispanic Blacks independent of HPV-association. In particular, for HPV-associated sites, HNC incidence for
Non-Hispanic White males aged 45–54 increased at the greatest rate, with an APC of 6.28% (p,0.05). Among non HPV-
associated sites, Non-Hispanic Black males aged 0–44 years experienced the greatest reduction in incidence (APC, 28.17%,
p,0.05), while a greater decline among the older, 55–64 year age group (APC, 25.44%, p,0.05) occurred in females.
Conclusions: This study provides evidence that HPV-associated tumors are disproportionately affecting certain age, sex and
race/ethnicity groups, representing a different disease process for HPV-associated tumors compared to non HPV-associated
tumors. Our study suggests that HPV tumor status should be incorporated into treatment decisions for HNC patients to
improve prognosis and survival.
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Introduction
In the United States, it is expected that 36,540 new cases of oral,
pharyngeal, and laryngeal cancer, also known as head and neck
cancer (HNC), will be diagnosed in 2010, and 7,880 deaths will
occur from HNC [1,2]. The term head and neck cancer represents
a broad range of anatomic sub-sites and often there is no
consensus as to what locations should be included under this all-
encompassing, yet generic label. However, customarily this term
includes the following anatomic locations: lip, tongue, gum, floor
of mouth, palate, oral cavity, salivary glands, tonsils, oropharynx,
nasopharynx, hypopharynx, nasal cavity, paranasal sinus, and
larynx.
HNC incidence, mortality, and relative survival rates vary with
respect to sex and race. Incidence and mortality rates are more
than twice as high in men as in women, and are greatest in men
who are older than 50 years of age [2,3]. African American men
have higher incidence and mortality rates for HNC compared to
White men. Incidence rates for African American and White
women are fairly similar, although African American women have
slightly higher mortality rates than White women [3,4]. While
there have been advances in treatment modalities, five-year
relative survival has remained low (61%) and relatively unchanged
for the past three decades [2,4,5]. Both incidence and mortality
rates depend upon the anatomic location of the tumor and vary
considerably. The tongue and oropharynx are the two anatomic
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tumor stage strongly influences survival. Localized tumors
demonstrate an approximate 83% five-year relative survival; in
contrast, regional tumors demonstrate a 54% five-year relative
survival and distant tumors have a 32% five-year relative survival
[2].
It is well known that intensity and duration of alcohol and
tobacco consumption are established risk factors for HNC. Over
80% of HNC cases are directly attributable to alcohol and tobacco
exposure, however, the other 15–20% of cases generally consist of
non-smokers and non-drinkers [7]. This suggests that other risk
factors besides alcohol and tobacco use are important in the
etiology of HNC. Recent epidemiological and experimental data
has implicated infection with human papillomavirus (HPV) in the
pathogenesis of HNC [8]. It has been reported that approximately
25% of all HNC are positive for HPV-DNA, with 90–95% of
those positive for HPV type 16 [8,9,10]. Applebaum, et al. [11]
have reported HPV type 16 seropositivity is associated with an
approximately four-fold increased risk of HNC. HPV detection
has been observed to vary considerably across HNC sub-sites, with
HPV prevalence significantly higher in the oropharynx and tonsil
than the oral cavity and larynx [9,10,11,12].
With the implication of HPV infection as an emergent risk
factor for HNC, it is crucial to describe the distribution and
incidence of HNC by sub-sites potentially associated with HPV
and those not associated with HPV. The disparity of HNC among
sex and race/ethnicity groups also needs better understanding to
determine the potential causes for such large differences in
incidence. This study uses 11 years of HNC incidence data (1995–
2005) from the North American Association of Central Cancer
Registries (NAACCR) Cancer in North America (CINA) Deluxe
Analytic Data to investigate HNC trends in incidence by potential
HPV-association with further stratification on age, sex and race/
ethnicity. In comparison to SEER data, a greater geographic
coverage and a larger sample size can be obtained with utilization
of the CINA data, allowing for more in-depth analyses. This may
yield patterns in HNC incidence that could not be seen in smaller
sample sizes. The objectives of our study were to assess the
incidence of HNC in the United States between 1995 and 2005
and to investigate incidence trends of HNCs putatively associated
with HPV infection.
Methods
Cases of HNC were identified through the NAACCR CINA
Deluxe Analytic Data for the diagnosis years 1995 to 2005. The
source of this data is from NAACCR data submissions as of
December 2007. Support for cancer registries is provided by the
state, province, or territory in which the registry is located. In the
U.S., registries also participate in the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER) Program or
the Centers for Disease Control and Prevention’s National
Program of Cancer Registries (NPCR) or both. To be included
in the CINA Deluxe Analytic Data file, data from the central
cancer registries must meet the NAACCR high quality standard
(either gold or silver) on completeness of case ascertainment (90%
or higher), passing edits (97% or greater), and other data quality
indicators. All data from the registries were analyzed as aggregate
data, and we excluded overlapping metropolitan areas to avoid
duplication of case counts. The registries included in this data set
are: Alabama, Alaska, Arizona, Arkansas, California, Colorado,
Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois,
Indiana, Iowa, Kentucky, Louisiana, Maine, Massachusetts,
Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada,
New Hampshire, New Jersey, New Mexico, New York, North
Dakota, Oklahoma, Oregon, Pennsylvania, Rhode Island, South
Carolina, Texas, Utah, Virginia, Washington and Wyoming. To
conduct the trend analyses, the data set was further restricted to
only those registries that contributed data to CINA Deluxe for the
complete 1995–2005 period. These registries are: Atlanta,
California, Colorado, Connecticut, Delaware, Florida, Hawaii,
Idaho, Illinois, Iowa, Kentucky, Louisiana, Maine, Michigan,
Minnesota, Nebraska, New Jersey, New Mexico, New York,
Pennsylvania, Rhode Island, Texas, Utah, Washington and
Wyoming. Georgia’s Cancer Registry did not contribute data
during 1995–1998 and therefore, were excluded in the trend
analysis. However, the City of Atlanta’s Cancer Registry
contributed data for the entire 1995–2005 time period, so this
subset of Georgia’s population was included in the trend analysis.
The Louisiana State University Health Sciences Center’s Institu-
tional Review Board and NAACCR’s Institutional Review Board
reviewed and approved this study to be exempt. Consent did not
need to be obtained since all data was de-identified and in an
aggregate data form.
The CINA Deluxe dataset uses a joint race/ethnicity variable
generated from race and ethnicity information found in medical
records, which were then enhanced by the NAACCR Hispanic
Identification Algorithm (NHIA) [13]. This joint race/ethnicity
variable has five categories: Hispanic/All Races, Non-Hispanic/
White, Non-Hispanic/Black, Non-Hispanic/Other and Non-
Hispanic/Unknown. The Non-Hispanic/Other and Non-Hispan-
ic/Unknown categories were excluded from the analysis since the
racial/ethnic status of these HNC cases could not be obtained
(7,077 cases, 2.6% of the total number of HNC cases).
Another important data issue occurs with the use of multiple
staging systems during the eleven year time period of data
collection. The stages of HNC diagnosed from 1995–2000 were
classified according to the 1977 SEER summary staging system
criteria, HNC diagnosed from 2001–2003 were classified accord-
ing to the 2000 SEER summary staging system, and HNC
diagnosed from 2004–2005 were classified according to the
derived 2000 SEER summary staging system. The use of multiple
staging systems can lead to potential misclassification and affect
the stage distribution of the population.
To identify cases in the CINA deluxe analytic data file between
1995 and 2005 with HNC (including all anatomical sites under the
heading of ‘‘lip, oral cavity, pharynx’’ and ‘‘larynx’’) we extracted
the following HNC sites according to the topography codes in the
International Classification of Diseases for Oncology, Third
Edition (ICD-O-3) [14]: tongue (C01.9–C02.9); gum (C03.0–
C03.9); floor of mouth (C04.0–C04.9); palate (C05.0–C05.9);
other and unspecified parts of the mouth (C06.0–C06.9); tonsil
(C09.0–C09.9); oropharynx (C10.0–C10.9); hypopharynx (C12.9,
C13.0–C13.9); other oral cavity and pharynx (C14.0, C14.2–
C14.8); and larynx (C32.0–C32.9). HNC cases eligible for this
analysis included incident, microscopically confirmed invasive
cancers. The majority of oral and pharyngeal cancers reported are
squamous cell in origin (95%), so we restricted the histology to
include only those cancers of squamous cell origin (ICD-O-3
morphology codes: 8050–8052, 8070–8076, and 8081–8084).
Three HNC sites, lip (C00.0–C00.9); salivary glands (C07.9–
C08.9); and nasopharynx (C11.0–C11.9), were excluded in the
analysis due to etiologic and histological differences from the other
sub-sites.
We also classified all HNC cases into two groups based on
proclivity for HPV infection: HPV-associated sites and non HPV-
associated sites. Since we were unable to determine the true HPV
status of the tumors we relied on professional expertise and
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potentially associated with HPV [7,9,12,15,16,17,18,19,20,21,22,
23]. Three distinct anatomic sub-sites were classified as potentially
associated with HPV. These three sites and their corresponding
ICD-O-3 codes are: the tonsil, including the Waldeyer ring
(C09.0–C09.9 and C142); the base of tongue and lingual tonsil
(C01.9 and C02.4); and parts of the oropharynx (C10.2–C10.9).
The remaining eligible HNC sites were included in the analysis as
non HPV-associated sites.
Statistical Analysis
Counts and percent distribution were computed by sex, age,
race/ethnicity, and cancer stage for all HNC sites, as well as those
sites associated with HPV infection and those sites not associated
with HPV infection. HNC incidence counts, age-adjusted
incidence rates (AAIR; number of new cases per 100,000
person-years standardized according to the US 2000 Standard
Population) and corresponding 95% confidence intervals (95%
CIs) were calculated by sex, race/ethnicity, cancer stage and
Table 1. Characteristics of study participants with incident HNC for HPV-Associated sites and non HPV-Associated sites by sex, age,
race/ethnicity
a and stage
b, 1995–2005.
All HNC Sites HPV-Associated Sites Non HPV-Associated Sites
Category Sub-Category Count % Count % Count %
Sex Male 200,497 73.4 53,391 77.5 147,106 72.0
Female 72,776 26.6 15,470 22.5 57,306 28.0
Age (Years) 0–44 16,398 6.0 5,447 7.9 10,951 5.4
45–54 52,587 19.2 18,874 22.4 33,713 16.5
55–64 75,754 27.7 20,719 30.1 55,035 26.9
65+ 128,534 47.0 23,821 34.6 104,713 51.2
Race/Ethnicity NH White 220,549 80.7 56,426 81.9 164,123 80.3
NH Black 30,100 11.0 7,286 10.6 22,814 11.2
Hispanic 15,547 5.7 3,650 5.3 11,897 5.8
Stage Localized 111,604 40.8 11,086 16.1 100,518 49.2
Regional 115,591 42.3 45,388 65.9 70,203 34.3
Distant 26,739 9.8 8,268 12.0 18,471 9.0
Unstaged 19,339 7.1 4,119 6.0 15,220 7.5
All 273,273 100 68,861 100 204,412 100
HNC: head and neck cancer; HPV: human papillomavirus; NH: Non-Hispanic.
aAny cases with an ‘Unknown’ or ‘Other’ race were not included in the analysis. Percentages for race/ethnicity will not total 100%.
bFor 1995–2000, SEER Summary Stage 1997 was used; for 2001–2003, SEER Summary Stage 2000 was used; for 2004–2005, Derived SEER Summary Stage 2000 was used.
doi:10.1371/journal.pone.0032657.t001
Table 2. Age-adjusted incidence rates of potentially HPV-associated and non HPV-associated HNC for males and females by age
and stage
a, 1995–2005.
Age-adjusted Incidence Rates (95% CI)
HPV-Associated Sites Non HPV-Associated Sites
Category Sub-Category Total Male Female Total Male Female
Age (Years) 0–44 0.36 (0.35–0.37) 0.56 (0.55–0.58) 0.16 (0.15–0.17) 0.72 (0.70–0.73) 0.98 (0.96–1.00) 0.45 (0.44–0.47)
45–54 5.91 (5.83–6.00) 10.14 (9.98–10.30) 1.85 (1.78–1.91) 10.57 (10.46–10.68) 16.52 (16.32–16.73) 4.84 (4.73–4.95)
55–64 9.73 (9.60–9.87) 16.35 (16.10–16.60) 3.64 (3.52–3.75) 25.86 (25.64–26.07) 41.07 (40.68–41.47) 11.85 (11.65–12.06)
65+ 7.94 (7.84–8.04) 12.90 (12.71–13.10 4.21 (4.11–4.30) 34.91 (34.70–35.12) 57.15 (56.73–57.57) 18.71 (18.51–18.91)
Stage Localized 0.46 (0.46–0.47) 0.71 (0.69–0.73) 0.25 (0.24–0.26) 4.21 (4.18–4.24) 6.84 (6.79–6.89) 2.10 (2.07–2.12)
Regional 1.90 (1.88–1.92) 3.21 (3.17–3.24) 0.74 (0.72–0.75) 2.94 (2.92–2.96) 4.56 (4.52–4.60) 1.56 (1.53–1.58)
Distant 0.35 (0.34–0.35) 0.59 (0.58–0.61) 0.13 (0.12–0.14) 0.77 (0.76–0.78) 1.27 (1.25–1.29) 0.36 (0.35–0.37)
Unstaged 0.17 (0.17–0.18) 0.28 (0.27–0.29) 0.08 (0.07–0.08) 0.64 (0.63–0.65) 1.01 (0.99–1.03) 0.34 (0.33–0.35)
All 2.88 (2.86–2.91) 4.79 (4.75–4.83) 1.20 (1.18–1.22) 8.56 (8.52–8.60) 13.67 (13.60–13.74) 4.35 (4.31–4.38)
HNC: head and neck cancer; HPV: human papillomavirus; 95% CI: 95% Confidence Interval.
Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard Population (19 age groups – Census P25-1130).
Confidence intervals (Tiwari model) are 95% for rates.
aFor 1995–2000, SEER Summary Stage 1997 was used; for 2001–2003, SEER Summary Stage 2000 was used; for 2004–2005, Derived SEER Summary Stage 2000 was used.
doi:10.1371/journal.pone.0032657.t002
Incidence of HPV-Associated HNC in U.S.
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32657Figure 1. Annual percent change for age-adjusted HNC incidence rates by age, 1995–2005. AAIR: age-adjusted incidence rate; HNC: head
and neck cancer; HPV: human papillomavirus; APC: annual percent change. *Rates are significantly different from zero (p,0.05). Rates are per 100,000
and age-adjusted to the 2000 US Standard Population (19 age groups – Census P25-1130). Annual percent change was calculated using the least
squares method. Only registries contributing data to the entire 1995–2005 period were used in the analysis.
doi:10.1371/journal.pone.0032657.g001
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rate ratios and corresponding 95% CIs were calculated using Non-
Hispanic Whites as the referent group. Lastly, we calculated the
annual percent change (APC) in incidence rates from 1995–2005
to assess whether incidence trends differ across time for HPV-
associated and non HPV-associated sites as well as age, sex and
race/ethnicity. All data analyses were conducted using the
SEER*Stat software, Version 6.2.4 (National Cancer Institute,
Bethesda, MD).
Results
As shown in Table 1, 273,273 HNC cases were reported by the
cancer registries included in the NAACCR CINA Deluxe Analytic
Data file during 1995 to 2005. The majority of the cases were male
(73.4%) and Non-Hispanic White (80.7%). Generally, HNC cases
were more commonly diagnosed at older age groups, with the
majority of cases diagnosed at 65 years of age or older (47.0%).
HNC was diagnosed more frequently at a regional or localized
stage (42.3% and 40.8% respectively), with 7.1% of the tumors
diagnosed lacking staging information. Similar distributions were
seen when cases were stratified into tumors potentially associated
with HPV infection, with the majority of cases being of older age,
male and Non-Hispanic White independent of HPV-association.
Although overall the majority of cases were diagnosed at older
ages, a difference in the age distribution is evident when stratifying
by potential HPV-association. For Non-HPV associated sites, a
little over half of the cases were diagnosed at 65 years or older
(51.2%), whereas for HPV-associated sites about a third of the
cases were diagnosed at the 55–64 year age group and the 65 and
older age group (30.1% and 34.6% respectively). Diagnosis of
regional stage tumors occurred more often among HNC cases
associated with HPV, compared to the diagnosis of localized
tumors occurring more frequently in non HPV-associated sites.
For HNC diagnosed in HPV-associated and non HPV-
associated sub-sites, specific patterns emerged with respect to age
(Table 2). Independent of HPV-association and sex, the 0–44 year
age group experienced the lowest AAIR compared to the older age
groups. Although the AAIRs for non HPV-associated sites are
steadily increasing as age increases, a different pattern is seen in
the AAIRs for the HPV-associated sites. Among the HNC
diagnosed in HPV-associated sites, the AAIRs peak in the 55–64
year age group (9.73; 95% CI, 9.60–9.87) and decrease in the 65
and older age group. However, the AAIRs for females with HNC
diagnosed in HPV-associated sites steadily increase with increasing
age as seen for non HPV-associated sites. The same trends with
respect to age can be seen over time by reviewing the APC in the
AAIR for HPV-associated sites and non HPV-associated sites by
age, shown in Figure 1. Over the eleven year time period,
incidence rates increased over time irrespective of age for HPV-
associated sites, while incidence rates decreased for non HPV-
associated sites. In HPV-associated sites, the incidence for the 45–
54 year age group increased at a greater rate than other age
groups (APC, 4.42%, p,0.05). In general, for HPV-associated
sites, the younger age groups experienced greater increases in
incidence over the eleven year time period than the older age
group. In non HPV-associated sites, the incidence for the 55–64
year age group decreased at a greater rate than the other age
groups (APC, 23.60%, p,0.05).
Table 2 also outlines the differences in incidence by stage for
HPV-associated sites and non HPV-associated sites. Across HPV-
associated sites, regional staged tumors had the highest AAIR
(1.90; 95% CI, 1.88–1.92), whereas for non HPV-associated sites,
tumors diagnosed at a localized stage had higher AAIRs (4.21;
95% CI, 4.18–4.24). For both HPV-associated and non HPV-
associated sites, tumors diagnosed at a distant stage had the lowest
incidence when excluding unstaged tumors. The same patterns are
evident when stage-specific incidence is stratified by sex.
Age-adjusted incidence rates of HNCs were highest among
Non-Hispanic Blacks, followed by Non-Hispanic Whites and
Hispanics (Table 3). The same patterns in race/ethnicity specific
incidence are seen independent of sex and HPV-association. For
all HNC sites, Non-Hispanic Blacks have a 25% increased risk of
diagnosis with HNC compared to Non-Hispanic Whites (RR,
1.25; 95% CI, 1.24–1.27); while Hispanics have a 29% reduced
risk of HNC diagnosis compared to Non-Hispanic Whites (RR,
0.71; 95% CI, 0.70–0.72). Non-Hispanic Blacks have significantly
higher incidence rates compared to Non-Hispanic Whites except
Table 3. Age-adjusted incidence rates and rate ratios of potentially HPV-associated and non HPV-associated HNC by sex and race/
ethnicity
a, 1995–2005.
Age-adjusted incidence rates (95% CI) Rate ratios (95% CI)
Category
Sub-
Category NH White NH Black Hispanic NH Black/NH White Hispanic/NH White
All HNC Sites Total 11.71 (11.66–11.76) 14.67 (14.50–14.84) 8.34 (8.21–8.48) 1.25* (1.24–1.27) 0.71* (0.70–0.72)
Males 18.56 (18.47–18.65) 26.45 (26.10–26.80) 14.61 (14.33–14.89) 1.43* (1.41–1.45) 0.79* (0.77–0.80)
Females 5.84 (5.79–5.89) 5.96 (5.82–6.10) 3.34 (3.22–3.46) 1.02 (1.00–1.05) 0.57* (0.55–0.59)
HPV-Associated Sites Total 3.04 (3.02–3.07) 3.45 (3.37–3.53) 1.83 (1.77–1.89) 1.13* (1.10–1.16) 0.60* (0.58–0.62)
Males 5.00 (4.95–5.05) 6.12 (5.96–6.29) 3.25 (3.13–3.38) 1.22* (1.19–1.26) 0.65* (0.63–0.68)
Females 1.27 (1.25–1.29) 1.39 (1.33–1.46) 0.64 (0.59–0.69) 1.10* (1.04–1.15) 0.51* (0.47–0.55)
Non HPV-Associated SitesTotal 8.67 (8.62–8.71) 11.22 (11.08–11.37) 6.51 (6.39–6.64) 1.30* (1.28–1.31) 0.75* (0.74–0.77)
Males 13.56 (13.48–13.63) 20.33 (20.02–20.64) 11.36 (11.11–11.61) 1.50* (1.48–1.52) 0.84* (0.82–0.86)
Females 4.57 (4.53–4.61) 4.57 (4.44–4.69) 2.69 (2.59–2.80) 1.00 (0.97–1.03) 0.59* (0.57–0.61)
HNC: head and neck cancer; HPV: human papillomavirus; 95% CI: 95% Confidence Interval; NH: Non-Hispanic.
Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard Population (19 age groups – Census P25-1130).
Confidence intervals (Tiwari model) are 95% for rates and ratios.
*The rate is significantly different than the rate for Non-Hispanic Whites (p,0.05).
aAny cases with an ‘Unknown’ or ‘Other’ race were not included in the analysis.
doi:10.1371/journal.pone.0032657.t003
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and neck cancer; HPV: human papillomavirus; APC: annual percent change; NHW: Non-Hispanic Whites; NHB: Non-Hispanic Blacks. *Rates are
significantly different from zero (p,0.05). Rates are per 100,000 and age-adjusted to the 2000 US Standard Population (19 age groups – Census P25-
1130). Annual percent change was calculated using the least squares method. Only registries contributing data to the entire 1995–2005 period were
used in the analysis.
doi:10.1371/journal.pone.0032657.g002
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non HPV-associated sites. The largest disparity between Non-
Hispanic Blacks and Non-Hispanic Whites occurs in males
diagnosed with HNC in a non HPV-associated site (RR, 1.50;
95% CI, 1.48–1.52). Hispanics have significantly lower incidence
rates compared to Non-Hispanic Whites for all sex and potential
HPV-association groupings. For Hispanics, the largest difference
in incidence compared to Non-Hispanic Whites occurs among
females, where there is about a 40% to 50% reduction in incidence
depending on HPV-association.
Figure 2 illustrates the APC in the AAIR for HPV-associated
sites and non HPV-associated sites by race/ethnicity for the years
1995 to 2005. A significant overall increase in incidence occurred
in HNC diagnosed in a HPV associated sub-site, an APC of
2.99%; in contrast, we found a significant overall decrease in
incidence during the same time period for the non-HPV associated
sub-sites (APC, 22.64%, p,0.05). When stratified by race/
ethnicity category, the increase in incidence among sub-sites
associated with HPV is mainly seen among Non-Hispanic Whites
(APC, 4.09%, p,0.05) and Hispanics (APC, 1.08%, p,0.05). In
contrast, the incidence for Non-Hispanic Blacks decreased
significantly at an APC of 21.19% over the same time period
among sub-sites associated with HPV. Among non HPV-
associated sites, HNC incidence significantly declined over the
eleven year time period independent of race/ethnicity, with the
largest decrease in incidence occurring among Non-Hispanic
Blacks (APC, 23.67%, p,0.05).
Further investigation of the trends in the APC of the AAIR by
HPV-association, age, sex and race/ethnicity can be found in
Figures 3 and 4. For HPV-associated sites, younger Non-Hispanic
Whites and Hispanics are experiencing the greatest increase in
incidence in the HNC rates compared to the older age groups. In
particular, the incidence rates for Non-Hispanic White males aged
45–54 years increased at the greatest rate, with an APC of 6.28%
(p,0.05). For Non-Hispanic Blacks, declines in incidence
occurred across all ages except for the older males (APC,
0.61%). Among Non-Hispanic Black males, the incidence rates
declined more rapidly in the younger age groups compared to the
older age groups. The Non-Hispanic Black females experienced
the greatest decline in incidence in the 55–64 year age group
(APC, 23.63%, p,0.05), while the incidence in the other age
groups remained fairly constant. For non HPV-associated sites,
declines in the incidence of HNC can be seen independent of age,
race/ethnicity and sex. The steepest decline in incidence for Non-
Hispanic Whites occurred in the 55–64 year age group
independent of sex, with an APC of 23.32% (p,0.05) for males
and an APC of 24.04% (p,0.05) for females. Young Non-
Hispanic Black males experienced the greatest reduction in
incidence (APC, 28.17%, p,0.05), while a greater decline among
the older, 55–64 year age group (APC, 25.44%, p,0.05)
occurred in females. A similar trend is evident for the Hispanics,
with the greatest decline in incidence among younger males and
older women.
Discussion
Our analysis of HNC incidence in the United States reinforces
previous observations that HNC incidence rates disproportionate-
ly affect men and Non-Hispanic Blacks [4,17,20,24,25,26,27]. We
also provide evidence that infection with HPV has dramatically
affected the disease distribution of HNC. In light of an overall
decrease in HNC over the past two decades, HNC sub-sites most
strongly associated with HPV have demonstrated a significant
increase in incidence over time relative to non HPV-associated
sites. One notable exception is the trend among Non-Hispanic
Blacks, where the APC for both HPV-associated and non HPV-
associated HNC sites demonstrates a downward trend over time.
Similar to other studies, we also found rapid increases in HNC
incidence among younger Non-Hispanic Whites and Hispanics in
HPV-associated sites, while relatively large declines in HNC
incidence occurred among non HPV-associated sites, particularly
among young Non-Hispanic Blacks [22,27,28].
We found that a greater proportion of the subjects in this study
with HNC in HPV-associated sites were diagnosed at younger
ages compared to non HPV-associated sites. Gillison, et al. also
reported a similar trend where HPV-positive patients were
younger by about 5 years on average when compared to HPV-
negative patients [29]. In a study by Ringstrom, et al., patients
who were positive for HPV type 16 were 8.4 years younger than
the HPV-negative group, and patients who were positive for HPV
type 16 were more likely to be less than 59 years of age [19]. Other
studies have shown similar findings with respect to age and HPV
[18,22]. There was also a similar pattern seen when HNC
incidence was plotted over time by age, where overall, younger age
groups had greater increasing trends in incidence for HPV-
associated sites compared to older age groups. These findings
suggest that HPV tumor status may be an important etiologic
factor in the diagnosis of HNC in younger adults.
Subjects diagnosed with HNC in HPV-associated sites were
more commonly diagnosed at a regional tumor stage compared to
non HPV-associated sites, which were more commonly diagnosed
at a localized stage. The same trend was seen among the stage-
specific AAIRs. Other studies have found similar results, with
HPV-related HNC cases diagnosed at more advanced stages than
non HPV-related sites [18,22]. Although HPV-positive HNC
cases are diagnosed at later stages, a meta-analysis of survival has
shown that HPV-positive HNC cases have a significantly
improved overall survival and a lower recurrence risk than
HPV-negative tumors [30]. Physicians should consider HPV
infection and the extent of disease associated with these tumors to
make treatment decisions based on each patient’s tumor
characteristics.
Since the 1980s, HNC incidence rates have been declining
[24,31,32,33]. In the current study, different trends were seen in
HNC incidence rates once stratified by potential HPV-association.
HPV-associated sites experienced an increase in incidence over the
eleven year time period, while a decreasing trend was seen for non
HPV-associated sites. Previous studies have also found similar
results when classifying HNC sub-sites by potential HPV-
association [17,22,27]. In a study on tonsillar cancer and HPV
infection, investigators demonstrated an increase in incidence of
tonsillar cancer and a parallel increase in HPV infection during
the same time period [21]. Shiboski, et al. did not classify sub-sites
based on HPV infection, but similar trends were seen with respect
to incidence trends by sub-site: tongue and tonsil incidence rates
Figure 3. Annual percent change for age-adjusted HNC incidence rates by age, sex and race/ethnicity for HPV-associated sites,
1995–2005. AAIR: age-adjusted incidence rate; HNC: head and neck cancer; HPV: human papillomavirus; APC: annual percent change; NHW: Non-
Hispanic Whites; NHB: Non-Hispanic Blacks. *Rates are significantly different from zero (p,0.05). Rates are per 100,000 and age-adjusted to the 2000
US Standard Population (19 age groups – Census P25-1130). Annual percent change was calculated using the least squares method. Only registries
contributing data to the entire 1995–2005 period were used in the analysis.
doi:10.1371/journal.pone.0032657.g003
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e32657have increased, whereas the incidence of other HNC sites has
decreased or remained constant [34].
Several studies have found that patients with HPV-positive
tumors are less likely to smoke and consume alcohol compared to
patients with HPV-negative tumors [7,10,11,18]. D’Souza, et al.
found that exposure to HPV increased the association with
oropharyngeal cancer regardless of tobacco and alcohol use [35].
This evidence suggests that the increase in HNC incidence among
HPV-associated sites may be caused by other exposures besides
tobacco and alcohol use. One such exposure that has been linked
to HPV infection in the literature is high-risk sexual behavior,
particularly oral-sex [10,12,18,29,35,36,37]. A similar association
was also found in HIV positive individuals, suggesting that HPV
can be transmitted in the oral cavity through sexual contact,
particularly oral-genital contact [38,39]. Patients engaging in high-
risk oral sex behaviors are more readily exposed to HPV, which
could lead to an increase in HNC incidence among HPV-
associated HNC sub-sites.
Stratifying incidence rates over time by race/ethnicity revealed
interesting patterns among certain race/ethnicity groupings.
Among HPV-associated sites, the increasing trend in HNC
incidence was mainly due to Non-Hispanic Whites. Interestingly,
HNC incidence rates for Non-Hispanic Blacks are decreasing
across HPV-associated sites as well as non HPV-associated sites. It
was shown that in a study of HIV positive individuals, Caucasians
had a greater risk of oral HPV infection than African Americans
[40]. These findings suggest that the disparity in HNC incidence
trends may be due to the disproportionate sexual behaviors among
different race/ethnicities. Furthermore, in a study on the sexual
behavior of men, Billy, et al. found that black men were less likely
to have performed and received oral sex than white men [41]. If
blacks are not engaging in high-risk sexual practices for oral HPV
infection as suggested by Billy, et al. [41], the disparity in HNC
incidence trends among HPV-associated sites for race/ethnicity
seen in this paper can be explained. Future studies should examine
the impact of sexual practices on HPV infection and the
differences in sexual practices by race to determine the effect on
HNC incidence rates.
There were several limitations to the current study. Due to the
nature of the CINA data, we were unable to obtain individual risk
factor and HPV level data on each HNC case. Inferences cannot
be made as to individual level characteristics, but this study
provides important information from a population perspective.
The second limitation, and the most notable, is the classification of
anatomic sub-sites as HPV-associated and non HPV-associated.
We were unable to determine the HPV status of each tumor, and
relied on previous literature to determine which anatomic sub-sites
were potentially associated with HPV. The classification of HPV-
association could result in misclassification; however without HPV
typing results on each individual, the classification of HPV tumor
status can only be estimated by previous etiologic knowledge
presented in the literature. Another limitation results from
unavailable data on tobacco or alcohol use within the cancer
registries. Without this knowledge, we cannot establish the effect of
tobacco and alcohol use on HNC incidence and infection with
HPV.
This study has shown that HNC cases associated with HPV
infection represent a different disease process and mechanism
compared to HNC cases caused by alcohol and tobacco use. The
findings of this study suggest that determination of HPV tumor
status could be important in the decision of treatment therapies for
patients. With the identification of HPV-tumor status, treatment
could be tailored to the individual patient to improve prognosis
and survival. In addition, the current treatment options could be
improved by development of vaccine-mediated therapy or the use
of biological modifiers for preservation therapy of organs within
the head and neck region.
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